Parallel Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Parallel Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,536	Closed	-$132K	–	2777
2019 Q4	$132K	Sell	5,536 -655	-11%	-$18.1K	0.01%	667
2019 Q3	$166K	Buy	6,191 +725	+13%	+$20.4K	0.01%	544
2019 Q2	$148K	Sell	5,466 -300	-5%	-$9.41K	0.01%	533
2019 Q1	$200K	Buy	5,766 +1,125	+24%	+$32.5K	0.02%	400
2018 Q4	$90K	Buy	4,641 +2,891	+165%	+$59.5K	0.01%	578
2018 Q3	$47K	Buy	1,750 +1,450	+483%	+$47.3K	0.01%	845
2018 Q2	$11K	Hold	300	–	–	﹤0.01%	1323
2018 Q1	$10K	Hold	300	–	–	﹤0.01%	1300
2017 Q4	$15K	Hold	300	–	–	﹤0.01%	1140
2017 Q3	$15K	Hold	300	–	–	﹤0.01%	1130
2017 Q2	$19K	Hold	300	–	–	﹤0.01%	1038
2017 Q1	$12K	Buy	+300	New	+$9.55K	﹤0.01%	1164

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Parallel Advisors's PTLA Position: Q1 2020 in Review

Parallel Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 5,536 shares — an estimated $132K sold.

Parallel Advisors first reported a position in PTLA in Q1 2017 and held it in 12 quarters. The position peaked at $200K in Q1 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

Parallel Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Parallel Advisors sold 5,536 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $132K.
Parallel Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 12 quarters.
Parallel Advisors's Portola Pharmaceuticals, Inc. position peaked at $200K in Q1 2019.
187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on Parallel Advisors's 13F filing for Q1 2020, filed 27 Apr 2020.